Iruplinalkib

伊鲁阿克

Report date: 2023/06/29 16:57:34
NME

Base Information

Drug NameIruplinalkib
Drug Alias Name依鲁奥克启欣可WX-0593FL-006
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/27
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A